BACKGROUND: Microwave ablation (MWA) is increasingly used to achieve local control for liver tumours. This study sought to examine a monocentric experience with MWA, with a primary hypothesis that primary tumour histology was a significant predictor of early recurrence. METHODS: Retrospective single-institution review identified consecutive patients with liver tumours treated by MWA. Cox proportional hazards models assessed significance of prognostic variables. RESULTS: Seventy-two patients (43 female, 60%) underwent 83 MWA procedures for 157 tumours. Tumour histologies included hepatocellular cancer (10 operations), colorectal metastases (39), metastatic carcinoid (20) and other (14). The median tumour size was 2.0 cm. A concomitant liver resection was performed in 50 cases (60%). Crude peri-operative morbidity and mortality rates were 16% and 1%, respectively. The median follow-up was 16 months. Ablations were complete for 149 out of 157 tumours (95%). The median overall and recurrence-free survivals were 36 and 18 months, respectively. There was no difference in time to recurrence between the primary tumour types. In multivariable models, recurrence-free survival was independently associated with the use of neoadjuvant [hazard ratio (HR): 2.90, 95% confidence interval (CI): 1.09-7.76, P = 0.034] and adjuvant chemotherapy (HR: 0.36, 95% CI: 0.15-0.82, P = 0.016). CONCLUSIONS: MWA is a safe and feasible approach for local control of liver tumours. While chemotherapy administration was associated with time to recurrence after MWA, larger studies are needed to corroborate these findings.
BACKGROUND: Microwave ablation (MWA) is increasingly used to achieve local control for liver tumours. This study sought to examine a monocentric experience with MWA, with a primary hypothesis that primary tumour histology was a significant predictor of early recurrence. METHODS: Retrospective single-institution review identified consecutive patients with liver tumours treated by MWA. Cox proportional hazards models assessed significance of prognostic variables. RESULTS: Seventy-two patients (43 female, 60%) underwent 83 MWA procedures for 157 tumours. Tumour histologies included hepatocellular cancer (10 operations), colorectal metastases (39), metastatic carcinoid (20) and other (14). The median tumour size was 2.0 cm. A concomitant liver resection was performed in 50 cases (60%). Crude peri-operative morbidity and mortality rates were 16% and 1%, respectively. The median follow-up was 16 months. Ablations were complete for 149 out of 157 tumours (95%). The median overall and recurrence-free survivals were 36 and 18 months, respectively. There was no difference in time to recurrence between the primary tumour types. In multivariable models, recurrence-free survival was independently associated with the use of neoadjuvant [hazard ratio (HR): 2.90, 95% confidence interval (CI): 1.09-7.76, P = 0.034] and adjuvant chemotherapy (HR: 0.36, 95% CI: 0.15-0.82, P = 0.016). CONCLUSIONS: MWA is a safe and feasible approach for local control of liver tumours. While chemotherapy administration was associated with time to recurrence after MWA, larger studies are needed to corroborate these findings.
Authors: Georgios C Sotiropoulos; Hauke Lang; Andrea Frilling; Ernesto P Molmenti; Andreas Paul; Silvio Nadalin; Arnold Radtke; Eirini I Brokalaki; Fuat Saner; Philip Hilgard; Guido Gerken; Christoph E Broelsch; Massimo Malagò Journal: Hepatogastroenterology Date: 2006 May-Jun
Authors: K Ohmoto; I Miyake; M Tsuduki; N Shibata; M Takesue; T Kunieda; S Ohno; M Kuboki; S Yamamoto Journal: Hepatogastroenterology Date: 1999 Sep-Oct
Authors: Krit Kitisin; Vignesh Packiam; Jennifer Steel; Abhinav Humar; T Clark Gamblin; David A Geller; J Wallis Marsh; Allan Tsung Journal: HPB (Oxford) Date: 2011-08-11 Impact factor: 3.647
Authors: T Seki; M Wakabayashi; T Nakagawa; T Itho; T Shiro; K Kunieda; M Sato; S Uchiyama; K Inoue Journal: Cancer Date: 1994-08-01 Impact factor: 6.860
Authors: Jason T Heckman; Michael B Devera; J Wallis Marsh; Paulo Fontes; Nikhil B Amesur; Shane E Holloway; Michael Nalesnik; David A Geller; Jennifer L Steel; T Clark Gamblin Journal: Ann Surg Oncol Date: 2008-08-12 Impact factor: 5.344
Authors: U Leung; D Kuk; M I D'Angelica; T P Kingham; P J Allen; R P DeMatteo; W R Jarnagin; Y Fong Journal: Br J Surg Date: 2014-10-09 Impact factor: 6.939
Authors: Timothy J Ziemlewicz; J Louis Hinshaw; Meghan G Lubner; Christopher L Brace; Marci L Alexander; Parul Agarwal; Fred T Lee Journal: J Vasc Interv Radiol Date: 2014-11-04 Impact factor: 3.464
Authors: M Samim; W Prevoo; B J de Wit-van der Veen; K F Kuhlmann; T Ruers; R van Hillegersberg; M A A J van den Bosch; H M Verkooijen; M G E H Lam; M P M Stokkel Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-08 Impact factor: 9.236
Authors: Robbert S Puijk; Alette H Ruarus; Laurien G P H Vroomen; Aukje A J M van Tilborg; Hester J Scheffer; Karin Nielsen; Marcus C de Jong; Jan J J de Vries; Babs M Zonderhuis; Hasan H Eker; Geert Kazemier; Henk Verheul; Bram B van der Meijs; Laura van Dam; Natasha Sorgedrager; Veerle M H Coupé; Petrousjka M P van den Tol; Martijn R Meijerink Journal: BMC Cancer Date: 2018-08-15 Impact factor: 4.430
Authors: Martijn R Meijerink; Robbert S Puijk; Aukje A J M van Tilborg; Kirsten Holdt Henningsen; Llenalia Garcia Fernandez; Mattias Neyt; Juanita Heymans; Jacqueline S Frankema; Koert P de Jong; Dick J Richel; Warner Prevoo; Joan Vlayen Journal: Cardiovasc Intervent Radiol Date: 2018-04-17 Impact factor: 2.740